EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 61 / Numéro 4 (Juillet-Août 2006) Thérapie, 61 4 (2006) 313-323 Références
Accès gratuit
Numéro
Thérapie
Volume 61, Numéro 4, Juillet-Août 2006
XXIes Rencontres Nationales de Pharmacologie Clinique de Giens, 16-18 octobre 2005
Page(s) 313 - 323
Section Affaires réglementaires/Regulatory System
DOI https://doi.org/10.2515/therapie:2006058
Publié en ligne 7 février 2007
  1. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medical Products. www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [Google Scholar]
  2. Zerhouni E. The NIH Roadmap. Science 2003; 302: 63-72 [CrossRef] [PubMed] [Google Scholar]
  3. Zerhouni E. Translational and clinical science – time for a new vision. NEJM 2005; 353: 1621-3 [CrossRef] [PubMed] [Google Scholar]
  4. Fischer A, Borensztein P, Roussel C. The Europen rare disease thertapeutic initiative. A PPP is promoting research on new treatments for rare diseases. PLoS Medicine 2005; 2: e243 [Google Scholar]
  5. Frantz S. PPPs succeeding in tackling neglected diseases. Nature Rev Drug Discov 2005; 4: 796 [Google Scholar]
  6. Rawlins MD. Cutting the cost of drug development ? Nature Rev Drug Discov 2004; 3: 360-4 [CrossRef] [Google Scholar]
  7. Ray WA, Stein CM. Reform of drug regulation – beyond an independent drug-safety board. NEJM 2006; 354: 194-200 [CrossRef] [Google Scholar]
  8. http://www.medichildren.net/ [Google Scholar]
  9. Donnelly F, Jehenson P. European Technology Platform on Innovative Medicines. Int J Pharm Med 2005; 19: 153-61 [CrossRef] [Google Scholar]
  10. SRA on http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed [Google Scholar]
  11. http://www.agence-nationale-recherche.fr [Google Scholar]
  12. Stossel TP. Regulating acaademic-industrial research relationships – solving problems or stifling progress ? NEJM 2005; 353: 1060-5 [CrossRef] [Google Scholar]
  13. http://www.orphanxchange.org/ [Google Scholar]
  14. http://www.pactepourlarecherche.fr/presse/2005/aaccarnot.pdf [Google Scholar]
  15. http://www.competitivite.gouv.fr [Google Scholar]
  16. Kola I, Landis J. Can the pharmaceurical industry reduce attrition rates ? Nature Rev Drug Discov 2004; 3: 711-5 [CrossRef] [PubMed] [Google Scholar]
  17. Nissim A. Gofur Y, Vesselier S et al. Methods for targeting biologicals to specific disease sites. Trends Mol Med 2004; 10: 269-74 [CrossRef] [PubMed] [Google Scholar]
  18. Fishman MC, Porter JA. A new grammar for drug discovery. Nature 2005; 437: 491-3 [CrossRef] [PubMed] [Google Scholar]
  19. Singer E. Personalized medicine prompts push to redisgn clinical trials. Editorial, Nature Med 2005; 11: 462 [Google Scholar]
  20. The Royal Society. Personalised medicines : hopes and reality. September 2005, pp 1-52. Access through http://www.royalsoc.ac.uk/document.asp?id=3780 [Google Scholar]
  21. Couvreur P et al. EUFEPS report : contribution of academic research to discovery and development of medicines : current status and future opportunities. Eur J Pharm Sci 2005; 24: 245-52 [Google Scholar]
  22. Marionnet AV. PME, innovations technologiques et secteurs d'application. Pharma-Biotech. OSEO-ANVAR, Direction Technologie Projets Européens, pp 1-43 (2004) [Google Scholar]
  23. http://www.eortc.be [Google Scholar]
  24. http://www.gereq.net [Google Scholar]
  25. http://www.orpha.net [Google Scholar]
  26. Demotes-Mainard J, Ohmann C : European Clinical Research Infrastructures Network : promoting harmonisation and quality in European clinical research. Lancet 2005; 365: 107-108 [Google Scholar]
  27. Demotes-Mainard J. et al. How to exploit existing assets and resources in Europe ? Report of the stakeholders forum on `How to establish a European Technology Platform for innovative medicines', Barcelona, April 21-22 (2005) [Google Scholar]
  28. LEEM/AD Little. Optimisation de l'attractivité de la France pour la production biologique. Comité Biotechnologie du Leem, 28 novembre 2005 [Google Scholar]
  29. Demotes-Mainard J, Chêne G, Libersa C, Pignon JP : Clinical research infrastructures and networks in France : report on the french ECRIN workshop. Thérapie 2005; 60: 183-99 [Google Scholar]
  30. Clément B, Grimaud JA, Deleuze JF, Postaire E. Le réseau des Centres de Ressources Biologiques Humains. Une infrastructure essentielle pour la recherche biomédicale en Europe. Thérapie 2005; 60: 351-4 [Google Scholar]
  31. Fitzgerald GA. Anticipating change in drug development : the emerging era of translational medicine and therapeutics. Nature Rev Drug Discov 2005; 4: 815-8 [CrossRef] [Google Scholar]
  32. Vlahakes GJ. The value of phase 4 clinical testing. NEJM 2006; 354: 413-5 [CrossRef] [Google Scholar]
  33. Remuzzi G, Schieppati A, Boissel JP, Garattini S, Horton R: Independent clinical research in Europe. Lancet 2004; 364: 17232-6 [Google Scholar]